- The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma: A phase Ib/II clinical trialBai, L.; Bai, Y.; Huang, M.; Shao, G.; Song, L.; Sun, M.; Wang, W.; Wu, J.; Xu, A.; Huang, L.; Liu, T.; Liu, W.; Wang, Z. M.; Li, B.; Xia, Y.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
- Tebotelimab, a PD-1/LAG-3 bispecific antibody, in patients with advanced hepatocellular carcinoma who had failed prior targeted therapy and/or immunotherapy: An open-label, single-arm, phase 1/2 dose-escalation and expansion study.Ren, Zhenggang; Guo, Yabing; Bai, Yuxian; Ying, Jieer; Meng, Zhiqiang; Chen, Zhendong; Gu, Shanzhi; Zhang, Jingdong; Liang, Jun; Hou, Xinfang; Li, Wei; Xu, Aibing; Hao, Chunyi; Zhang, Jian; Xing, Ruijun; Zhang, Xinyu; Zhang, Dan; Chan, Stephen LamGenitourinary Cancers Symposium, San Francisco, CA, 2023-01-19 To 2023-01-21.被引 3
- Donafenib combined with anti-PD-1 antibodies plus transarterial therapy for initially unresectable hepatocellular carcinomaWen, Yaohong; Fu, Shunjun; He, Guolin; Cai, Lei; Liu, Yahong; Li, Xinmin; Xu, Yuyan; Wang, Chunming; Zhong, Kaihang; Zhang, Cheng; Xie, Qingyu; Pan, MingxinAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
会议论文
Anti-PD1 antibody pucotenlimab in combination with bevacizumab or lenvatinib in a phase II study for the treatment of advanced hepatocellular carcinoma (aHCC).
6阅读
